Table 4 The characteristic of health utility measurements
Category | Characteristic | Number of utility measures (n = 4821) | |
|---|---|---|---|
n | % | ||
Time of administer | < 6 months | 1078 | 22.36 |
6–12 months | 2233 | 46.32 | |
> 12–24 months | 626 | 12.98 | |
> 24 months | 884 | 18.34 | |
Measures | EORTC | 3141 | 65.15 |
FACT | 584 | 12.11 | |
SF-36 | 466 | 9.67 | |
QLI | 59 | 1.22 | |
FLIC | 55 | 1.14 | |
EQ-5D | 37 | 0.77 | |
Others | 479 | 9.94 | |
Country | Sweden | 929 | 19.27 |
USA | 621 | 12.88 | |
China | 477 | 9.89 | |
Netherland | 362 | 7.51 | |
Germany | 358 | 7.43 | |
Canada | 258 | 5.35 | |
Norway | 227 | 4.71 | |
France | 148 | 3.07 | |
Denmark | 142 | 2.95 | |
The UK | 124 | 1.16 | |
Others | 609 | 25.78 | |
Study design | Longitudinal | 2468 | 51.19 |
Cohort | 687 | 14.25 | |
Case-control | 256 | 5.31 | |
Randomized control trial | 1410 | 29.25 | |
Intervention | Pharmacological group | 3019 | 62.62 |
Non-pharmaceutical group | 1802 | 37.38 | |
Type of cancer | Breast Cancer | 787 | 16.32 |
Lung Cancer | 737 | 15.29 | |
Head and Neck Cancer | 688 | 14.27 | |
Research evaluating more than one type of cancer | 540 | 11.20 | |
Prostate Cancer | 406 | 8.42 | |
Esophageal or gastroesophageal junction | 230 | 4.77 | |
Ovarian Cancer | 135 | 2.80 | |
Gastric Cancer | 122 | 2.53 | |
Others | 1176 | 24.39 | |